Search Results - "Messinger D"

Computational Approaches to Understanding Interaction and Development

Authors: Messinger, D. S. Perry, L. K. Mitsven, S. G. et al.

Source: Grantee Submission. 2022.

Peer Reviewed: Y

Page Count: 64

Sponsoring Agency: National Institute on Deafness and Other Communication Disorders (NIDCD) (DHHS/NIH)
Institute of Education Sciences (ED)
National Science Foundation (NSF)

Descriptors: Artificial Intelligence, Computation, Measurement Techniques, Automation, Assistive Technology, Audio Equipment, Preschool Children, Autism Spectrum Disorders, Developmental Disabilities, Peer Relationship, Child Language, Child Behavior, Predictor Variables, Social Behavior, Diagnostic Tests, Observation

Assessment and Survey Identifiers: Autism Diagnostic Observation Schedule

IES Funded: Yes

Cocaine Exposure Is Associated with Subtle Compromises of Infants' and Mothers' Social-Emotional Behavior and Dyadic Features of Their Interaction in the Face-to-Face Still-Face Paradigm

Authors: Tronick, E. Z. Messinger, D. S. Weinberg, M. K.

Source: Developmental Psychology. Sep 2005 41(5):711-722.

Peer Reviewed: Y

Page Count: 12

Descriptors: Models, Infants, Mothers, Effect Size, Emotional Development, Drug Use, Prenatal Influences, Perinatal Influences, Social Development, Parent Child Relationship, Affective Behavior

Access URL: https://content.apa.org/journals/dev/41/5

This result is not displayed to guests.
Login for full access.

A baseline tool for predicting response to peginterferon alfa‐2a in HBeAg‐positive patients with chronic hepatitis B.

Authors: Chan, H. L. Y. Messinger, D. Papatheodoridis, G. V. et al.

Source: Alimentary Pharmacology & Therapeutics. Sep2018, Vol. 48 Issue 5, p547-555. 9p. 3 Charts, 3 Graphs.

This result is not displayed to guests.
Login for full access.

Peginterferon alfa-2a (40kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients.

Authors: Reddy, K. R. Messinger, D. Popescu, M. et al.

Source: Journal of Viral Hepatitis. Oct2009, Vol. 16 Issue 10, p724-731. 8p. 4 Charts, 3 Graphs.

Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial.

Authors: Wollert KC Meyer GP Lotz J et al.

Source: Lancet. 7/10/2004, Vol. 364 Issue 9429, p141-148. 8p.

Prenatal drug exposure and maternal and infant feeding behaviour.

Authors: LaGasse, L. L. Messinger, D. Lester, B. M. et al.

Source: Archives of Disease in Childhood -- Fetal & Neonatal Edition. Sep2003, Vol. 88 Issue 5, pF391-F399. 9p. 7 Charts.

Progress in thermoset molding.

Authors: Messinger, D. L. Jost, H. D.

Source: Plastics Technology; October 1968, Vol. 14, p57-58, 2p

828 TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN OLDER HCV GENOTYPE 1 PATIENTS WITH POSITIVE PROGNOSTIC FACTORS LEADS TO HIGH RATES OF SUSTAINED VIROLOGICAL RESPONSE

Authors: Reddy, K.R. Messinger, D. Popescu, M. et al.

Source: Journal of Hepatology. May2008 Supplement 2, Vol. 48, pS310-S310. 1p.

Dyadic Synchrony and Responsiveness Within the Context of Elevated Autism Likelihood: Applying Time-Varying Effect Models.

Authors: Kellerman, A. Janis, A. Piergies, A. et al.

Source: Journal of Autism & Developmental Disorders. Jun2025, p1-18.

Responses are durable for up to 5 years after completion of peginterferon alfa‐2a treatment in hepatitis B e antigen‐positive patients.

Authors: Chuang, W.‐L. Jia, J. Chan, H. L. Y. et al.

Source: Alimentary Pharmacology & Therapeutics. May2018, Vol. 47 Issue 9, p1306-1316. 11p. 1 Diagram, 4 Charts, 2 Graphs.

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.

Authors: Brodowicz, T Lang, I Kahan, Z et al.

Source: British Journal of Cancer. 11/25/2014, Vol. 111 Issue 11, p2051-2057. 7p. 4 Charts, 2 Graphs.

Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon α-2a plus ribavirin.

Authors: Reddy, K. R. Govindarajan, S. Marcellin, P. et al.

Source: Journal of Viral Hepatitis. Feb2008, Vol. 15 Issue 2, p129-136. 8p. 1 Diagram, 2 Charts, 3 Graphs.

Treatment with Recombinant Human Erythropoietin in Patients with Aluminum Overload and Hyperparathyroidism.

Authors: Grützmacher, P. Ehmer, B. Limbach, J. et al.

Source: Blood Purification. 1990, Vol. 8 Issue 5, p279-284. 6p.

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.

Authors: Brodowicz, T. Ciuleanu, T. E. Radosavljevic, D. et al.

Source: Annals of Oncology. Jul2013, Vol. 24 Issue 7, p1769-1777. 9p. 1 Diagram, 4 Charts, 1 Graph.

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

Authors: Lang, I. Inbar, M.J. Kahán, Z. et al.

Source: European Journal of Cancer. Nov2012, Vol. 48 Issue 17, p3140-3149. 10p.

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.

Authors: Jensen DM Marcellin P Freilich B et al.

Source: Annals of Internal Medicine. 4/21/2009, Vol. 150 Issue 8, p528-540. 13p.

Streamlining the diagnosis of autism spectrum disorder for the National Children's Study.

Authors: Stone, W.L. Ibanez, L. Newschaffer, C. et al.

Source: Neurotoxicology & Teratology. May2014, Vol. 43, p77-78. 2p.

P697 SERUM LEVELS OF HEPATITIS B SURFACE ANTIGEN (HBsAg) PREDICT HEPATIC FIBROSIS SEVERITY IN E ANTIGEN-POSITIVE CHRONIC HEPATITIS B (HBeAg+VE CHB) PATIENTS.

Authors: Marcellin, P. Martinot-Peignoux, M. Lau, G. et al.

Source: Journal of Hepatology. Apr2014 Supplement, Vol. 60, pS301-S301. 1p.